A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients
Trastuzumab has been widely used among the breast cancer patients with human epidermal growth factor receptor 2 (HER2) overexpression. The genetically engineered trastuzumab traded as Cipterbin® was developed in China since 2003. We have disclosed the phase I clinical trial data of safety, pharmacok...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Springer International Publishing
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4688281/ |